Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 367Ovarian Neoplasms 99Lung Neoplasms 98Neoplasms 84Small Cell Lung Carcinoma 71Breast Neoplasms 59Neoplasm Metastasis 49Triple Negative Breast Neoplasms 46Parkinson Disease 4, Autosomal Dominant Lewy Body 41Fallopian Tube Neoplasms 38Squamous Cell Carcinoma of Head and Neck 33Endometrial Neoplasms 30Carcinoma 30Uterine Cervical Neoplasms 28Colorectal Neoplasms 24Carcinoma, Ovarian Epithelial 23Head and Neck Neoplasms 19Carcinoma, Transitional Cell 18Urinary Bladder Neoplasms 17Advanced Solid Tumors 17Recurrence 15Melanoma 14Stomach Neoplasms 13Peritoneal Neoplasms 13Pancreatic Neoplasms 12Adenocarcinoma 11Lung Diseases 9Glioblastoma 9Carcinoma, Squamous Cell 9Thoracic Neoplasms 8

Interventions

ganitumab 3Paclitaxel 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2conatumumab 1Sorafenib 1Receptor Protein-Tyrosine Kinases 1Istiratumab 1Carboplatin 1BIIB022 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Insulin-Like Growth Factor I, Resistance To × Carboplatin × Clear all
NCT00807612 2024-09-25

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

NantCell, Inc.

Phase 1/2 Terminated
15 enrolled 11 charts

Insulin-Like Growth Factor I, Resistance To

Data powered by HemOnc (CC BY 4.0) Colophon âš¡